Phase 1/2 study of eprenetapopt (APR-246) in combination with pembrolizumab in patients with solid tumor malignancies.Ecaterina E. Dumbrava, Haeseong Park, Xīn Gào et al.|Journal of Clinical Oncology|2021Cited by 3